Condition: MASH - Metabolic Dysfunction-Associated Steatohepatitis · Sponsor: Madrigal Pharmaceuticals, Inc.
To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
This description comes directly from the study's public registry record.
Madrigal Pharmaceuticals · 800-905-0324 · MHGSafety@iconplc.com
Always discuss trial participation with your own doctor first.
| Madrigal Pharmaceuticals | West Conshohocken, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07541469